Development of IL-5 Receptor Antagonists

Title: Development of IL-5 Receptor Antagonists

Volume: 8 Issue: 20

Author(s): Iain Uings and Murray McKinnon

Affiliation:

Keywords: receptor antagonists, granulocyte-macrophage, bronchial hyperreactivity, constrained peptides

Abstract: A wealth of both clinical and pre-clinical data has strongly implicated the eosinophil in the pathogenesis of asthma, highlighting this cell type as a potential target for novel anti-inflammatory approaches to asthma therapy. The Th2 lymphocyte derived cytokine Interleukin-5 (IL-5) has emerged as the key regulator of eosinophil production, thus identifying IL-5 as the principal molecular target for therapeutic intervention. This review highlights both the pharmaceutical approaches, and the major challenges, to the identification of small molecule and protein antagonists of the IL-5 receptor. Using examples of known inhibitors we discuss their current status and highlight the major development hurdles in progressing these molecules into the market place.

Cite this article as:

Uings Iain and McKinnon Murray, Development of IL-5 Receptor Antagonists, Current Pharmaceutical Design 2002; 8 (20) . https://dx.doi.org/10.2174/1381612023393800